Get the Stockscreener App
20.49
3.28%
0.65
Pre-market:
20.66
0.17
+0.83%
Bioage Labs Inc stock is traded at $20.49, with a volume of 666.22K.
It is up +3.28% in the last 24 hours and up +16.02% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
See More
Previous Close:
$19.84
Open:
$19.84
24h Volume:
666.22K
Relative Volume:
1.46
Market Cap:
$910.84M
Revenue:
$10.32M
Net Income/Loss:
$-89.93M
P/E Ratio:
-8.5148
EPS:
-2.4064
Net Cash Flow:
$-88.63M
1W Performance:
+29.68%
1M Performance:
+16.02%
6M Performance:
+63.79%
1Y Performance:
+367.81%
1-Day Range:
$19.29
$21.26
1-Week Range:
$15.13
$21.26
52-Week Range:
$4.065
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
20.49 | 881.94M | 10.32M | -89.93M | -88.63M | -2.4064 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Needham | Buy |
| Feb-25-26 | Initiated | Oppenheimer | Outperform |
| Feb-18-26 | Upgrade | Jefferies | Hold → Buy |
| Jan-27-26 | Initiated | Piper Sandler | Overweight |
| Dec-05-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
BIOA News | BIOAGE LABS INC (NASDAQ:BIOA) - ChartMill
BioAge Labs (BIOA) director receives 22,000 stock options at $15.48 strike - Stock Titan
Director at BioAge Labs (BIOA) receives grant of 22,000 stock options - Stock Titan
BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (BIOA) director receives grant of 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director granted 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director awarded 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (NASDAQ: BIOA) shareholders elect directors and ratify KPMG at 2026 meeting - Stock Titan
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securi - GuruFocus
BioAge Labs eyes key BGE-102 readouts in heart risk and diabetic eye disease - MSN
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease - MarketBeat
BIOA Technical Analysis & Stock Price Forecast - Intellectia AI
BIOA: BGE-102 advances as a differentiated NLRP3 inhibitor with pivotal data expected by year-end - TradingView
BioAge Labs stock gains after positive early data and pipeline plans - MSN
BioAge Labs, Inc.Common Stock (NQ: BIOA - FinancialContent
BIOA Initiated by Roth Capital -- Price Target Set at $36.00 - GuruFocus
Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target - marketscreener.com
Roth MKM Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $36 - Moomoo
Roth/MKM initiates BioAge Labs stock coverage with buy rating - Investing.com
Roth/MKM initiates BioAge Labs stock coverage with buy rating By Investing.com - Investing.com India
BIOA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewswire
BioAge executives to speak at Jefferies and Goldman healthcare forums - Stock Titan
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - Insider Monkey
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Shareholders that lost money on BioAge Labs, Inc.(BIOA) should c - GuruFocus
Khosla affiliates hold 1.8M shares in BioAge Labs (NASDAQ: BIOA), 4.0% stake - Stock Titan
Cormorant Asset Management reports 6.51% stake in BioAge Labs (BIOA) - Stock Titan
BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union
Number of shareholders of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
BioAge Labs : BIOA - 24/7 Wall St.
Inside the cell-based Klotho therapy aiming to restore a longevity protein - Stock Titan
BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS - Fierce Biotech
BTIG initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN
BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo
BioAge Labs, Inc (BIOA) Stock News & Articles - 24/7 Wall St.
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - Yahoo Finance
BTIG Initiates BioAge Labs at Buy With $40 Price Target - marketscreener.com
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
TradingKey - TradingKey
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge Labs Releases Q1 2026 Financial Results - AlphaStreet
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - Barchart.com
BioAge Labs 1Q Research and Development Expenses Approximately $20.4M >BIOA - Moomoo
BioAge Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioAge Labs 1Q Loss/Shr 52c >BIOA - Moomoo
BioAge Labs Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
BioAge Labs Reports Positive Phase 1 Results for BGE-102 and Plans Upcoming Clinical Trials in Cardiovascular Risk and Diabetic Macular Edema - Quiver Quantitative
Bioage Labs Inc Stock (BIOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioage Labs Inc Stock (BIOA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Option Exercise |
5.05 |
8,820 |
44,572 |
8,820 |
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Sale |
17.81 |
8,820 |
157,084 |
0 |
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):